AKERO THERAPEUTICS IN

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

12 May 2025 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

10 May 2025 10:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

09 May 2025 07:41:09 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

09 May 2025 07:11:31 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

09 May 2025 06:15:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

07 May 2025 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

30 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

28 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

30 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

28 Jan 2025 21:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

27 Jan 2025 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

27 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

24 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

15 Nov 2024 11:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

13 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

21 Oct 2024 07:00:00 By Nasdaq GlobeNewswire